GlassScriptPhysician profile
Scott Yasinow
NPI 1932529872
$6,983.31
in general payments reported to CMS, 2019-2025
43 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $179 · 2021: $363 · 2022: $841 · 2023: $1,516 · 2024: $1,587 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,193.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $794.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $751.18 | 2021-2025 | Ubrelvy, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals LP | $697.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $691.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $554.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $410.66 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $358.18 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.03 | 2022-2025 | |
| Astellas Pharma US INC | $220.21 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.33 | 2019-2024 | Ofev, Tradjenta, Jardiance |
| Abbott Laboratories | $189.91 | 2022-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $183.90 | 2022-2025 | Eliquis, Camzyos |
| Dynavax Technologies Corporation | $168.81 | 2023-2025 | Heplisav-B |
| Exact Sciences Corporation | $137.71 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $133.46 | 2023-2025 | Dexcom G6 Transmitter |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Yasinow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.